Table 2.
Diagnosis confirmation, laboratory and radiological findings of pediatric patients with COVID-19.
| Non-MIS-C (n = 69) | MIS-C (n = 10) | |||||
|---|---|---|---|---|---|---|
| Etiological diagnosis, number tested (n) | n | Positive, n (%) | No. | Positive, n (%) | No. | Positive, n (%) |
| SARS-CoV-2 infection | ||||||
| RT-PCR | 69 | 67 (85) | 10 | 5 (50) | 79 | 72 (91) |
| Serology | ||||||
| IgM | 5 | 4 (80) | 8 | 1 (13) | 13 | 5 (45) |
| IgG | 5 | 3 (60) | 8 | 5 (63) | 13 | 8 (62) |
| IgM and IgG | 5 | 2 (40) | 8 | 0 (0) | 13 | 1 (8) |
| Co-detection with COVID-19 | ||||||
| Rapid test for respiratory syncytial virus | 25 | 2 (8) | 1 | 0 (0) | 26 | 2 (8) |
| Other virus | 18 | 2 (11) | 3 | 0 (0) | 21 | 2 (10) |
| Human rhinovirus | 2 | 1 (50) | 0 | 0 (0) | 2 | 1 (50) |
| Parainfluenza 4 + Bordetella parapertussis | 2 | 1 (50) | 0 | 0 (0) | 2 | 1 (50) |
| Blood test, number tested (n) | n | Worse values | Worse values | n | Worse values | |
| Median (IRQ) or | Median (IRQ) or | Median (IRQ) | ||||
| Total leukocyte count (× 1000/µL) | 66 | 11,850 (7933−18,075) | 10 | 18,275 (14,293−23,868) | 76 | 12,520 (8382−19,100) |
| Platelet count (× 1000/µL) | 66 | 260,500 (159,250−374,500) | 10 | 103,000 (78,750−177,500) | 76 | 226,500 (136,750−367,000) |
| Lymphopenia n (%) | 59 | 21 (36) | 10 | 5 (50) | 69 | 26 (38) |
| C-reactive protein (mg/dL), | 63 | 3 (0.6−18) | 10 | 10 (9−30) | 73 | 5.1 (0.7−20.0) |
| Erythrocyte sedimentation rate (mm/1st h) | 5 | 68 (45−85) | 9 | 100 (49−120) | 14 | 88 (46−115) |
| Lactic dehydrogenase (U/L) | 30 | 395 (290−612) | 8 | 630 (545−844) | 38 | 433 (294−737) |
| D-dimer (ng/mL) | 22 | 1723 (441−3966) | 8 | 3755 (2170−5099) | 30 | 1953 (1099–4099) |
| Procalcitonin (ng/mL) | 1 | 0.4 (0.4−0.4) | 2 | 15.7 (8−23.3) | 3 | 0.4 (0.4−15.7) |
| Urea (mg/dL) | 58 | 23 (16−35) | 10 | 33 (22−45) | 68 | 24 (16−38) |
| Creatinine (mg/dL) | 59 | 0.4 (0.3−0.6) | 10 | 0.5 (0.4−0.7) | 69 | 0.5 (0.3−0.6) |
| Albumin (g/dL) | 36 | 3.2 (2–4) | 6 | 2.8 (2.4−3.2) | 42 | 3.2 (2.3−3.8) |
| Alanine aminotransferase (U/L) | 49 | 28 (15−55) | 9 | 54 (41−70) | 58 | 41 (15−57) |
| Aspartate aminotransferase (U/L) | 49 | 40 (31−75) | 10 | 51 (29−67) | 59 | 42 (31−73) |
| Creatinine kinase, total (U/L) | 14 | 72 (35−347) | 8 | 67 (47−147) | 22 | 68 (44−170) |
| Creatinine kinase, myocardial band (U/L) | 12 | 27 (22−46) | 3 | 20 (11−24) | 15 | 26 (21−42) |
| Troponin (ng/mL) | 9 | 0.4 (0−5) | 8 | 0.0 (0.0−0.4) | 17 | 0.1 (0.0−1.0) |
| Ferritin (ng/mL) | 17 | 648 (198−974) | 7 | 228 (143−1366) | 24 | 594 (190−1030) |
| ProBNP (pg/mL) | 0 | – | 7 | – | 7 | 5829 (2962−10,027) |
| Interleukin-6 (pg/mL) | 0 | – | 2 | 453 (323−582) | 2 | 453 (323−582) |
| Radiological findings upon PICU admission | n | Altered images | Altered images | Altered images | ||
| Abnormal chest radiographies | 58 | 35 (60) | 10 | 7 (70) | 68 | 42 (62) |
| Diffuse interstitial infiltrate, bilateral | 35 | 21 (60) | 7 | 4 (57) | 42 | 25 (60) |
| Interstitial infiltrate, localized | 35 | 6 (17) | 7 | 0 (0) | 42 | 6 (14) |
| Consolidation | 35 | 5 (14) | 7 | 2 (29) | 42 | 7 (17) |
| Atelectasis | 35 | 3 (9) | 7 | 0 (0) | 42 | 3 (7) |
| Pleural effusion | 35 | 3 (9) | 7 | 3 (43) | 42 | 6 (14) |
| Hyperinflation | 35 | 4 (11) | 7 | 0 (0) | 42 | 4 (10) |
| Chest CT with ground-glass opacities | 31 | 18 (58) | 7 | 1 (14) | 38 | 19 (50) |
COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription polymerase chain reaction; IgM, immunoglobulin M; IgG, immunoglobulin G; IQR, interquartile range; proBNP, pro-B type natriuretic peptide; PICU, pediatric intensive care unit, CT, computed tomography.